乳链菌肽前体基因（nisZ）在乳酸乳球菌中的克隆和表达

用PCR技术从克隆有完整乳链菌肽生物合成基因簇（来自于乳链菌肽高产菌株L.lactis AL2)的重组噬菌体λHJ-3中扩增了编码乳链菌肽的前体基因,与pMG36e连接得到重组质粒pHJ201,用电击转化法将pHJ201转化到L.lactis NZ9800中,经活性测定和Tricine－SDS－PAGE电泳证实乳链菌肽前体基因获得了功能表达。DNA序列分析表明乳链菌肽高产菌株L.lactis AL2产生的是NisinZ。发现pHJ201d L.lactis NZ9800 中有良好的稳定性。     

Pfk基因过表达对乳酸乳球菌N8产nisin速率的影响

【目的】通过基因工程手段增加糖酵解途径中编码限速酶6-磷酸果糖激酶基因Pfk在乳酸链球菌素(nisin)产生菌Lactococcus lactis N8中的表达,增快nisin的产生,从而提高单位时间内nisin的产量,缩短发酵周期。【方法】将pfk基因及编码以c AMP为依赖的蛋白激酶催化亚基基因pka C克隆到表达质粒p MG36e上,将共表达重组质粒转入L.lactis N8中,使Pfk-pka C基因过量表达,得到重组菌株L.lactis N8-p MG36epfk-pka C,并比较该重组菌株与野生菌的生长曲线、胞内6-磷酸果糖激酶活性、发酵上清液的抑菌活性及效价,并从转录水平分析两株菌nis A及pfk-pka C的转录差异,比较野生菌与重组菌在不同葡萄糖含量下培养产nisin的变化。【结果】Pfk基因与pka C基因的过表达对重组菌的生长速度没有明显的影响,却能提高重组菌产nisin的速度,在发酵10 h时nisin的产量比野生菌提高了20%,使得发酵周期缩短近2 h。野生菌及重组菌在不同葡萄糖含量下培养发酵上清液的nisin效价没有明显的变化。【结论】糖酵解途径中6-磷酸果糖激酶基因Pfk的过表达可以加快乳酸乳球菌N8产nisin的速率,缩短发酵周期。     

通过定点突变提高乳链菌肽对热及pH的稳定性

【目的】通过定点突变技术改变乳链菌肽(nisin)特定位置氨基酸,获得性质改善的nisin突变体,为扩大其应用范围提供依据。【方法】在抑菌谱扩大的nisin单突变体M21K nisinZ的基础上,对M21K nisZ基因第29位丝氨酸密码子进行定点突变;将其克隆至乳酸菌表达载体pMG36e,并在Lactococcus lactis NZ9800中进行表达;双突变体M21K/S29K nisinZ经分离纯化后检测其在抑菌活性、抑菌谱和稳定性等方面的变化。【结果】与单突变体M21K nisinZ及野生型nisinZ(wild-type,WT)相比,双突变体M21K/S29K nisinZ对指示菌的抑菌活性虽有所下降,但其对温度及pH值的稳定性有显著提高。同时其抑菌谱与M21K nisinZ相同,可抑制革兰氏阴性菌,扩大了WT的抑菌谱。【结论】通过改变nisin分子特定位置的氨基酸可以改善nisin分子的理化性质,有可能得到应用范围更广的nisin品种。     

乳链菌肽细胞分子传感器的构建与应用

【背景】乳链菌肽主要是由乳酸乳球菌生产的一类多肽,对革兰氏阳性菌有抑菌作用,是目前联合国粮食及农业组织/世界卫生组织唯一批准使用的天然食品防腐剂。但是其产量低、缺乏简便高效的检测方法,限制了其研究和应用。【目的】构建一种可输出肉眼可见红色荧光的细胞分子传感器,以期能简单方便地检测样品中的乳链菌肽,同时应用该传感器筛选乳链菌肽生产菌株。【方法】用Golden-Gate克隆方法构建含乳链菌肽诱导启动子和下游红色荧光蛋白基因(两种)的载体,转入Lactococcus lactis中。用细胞传感器筛选可能的乳链菌肽生产菌株。【结果】构建的两种乳链菌肽细胞分子传感器都能对2?200 ng/mL乳链菌肽有灵敏的响应,可用于定量测定。两种传感器的最大荧光强度和表型也有所不同。利用细胞传感器确定了Lactococcus lactis ATCC 11454乳链菌肽的产生,同时排除了一个能产其他抗菌化合物的菌株。【结论】构建的细胞分子传感器能特异性地响应乳链菌肽,并能简单快速地筛选乳链菌肽菌株。     

精氨酸代谢途径抗酸关键基因对乳酸乳球菌Lactococcus lactis NZ9000胁迫抗性的影响

【目的】寻找精氨酸代谢途径中与酸胁迫相关的关键作用因素。【方法】通过在Lactococcus lactis NZ9000中分别过量表达来源于Lactobacillus casei Zhang的精氨酰琥珀酸合成酶(ASS)和精氨酰琥珀酸裂解酶(ASL)改变精氨酸代谢提高酸胁迫抗性。【结果】与对照菌株对比,重组菌株在环境胁迫下表现了较高的生长性能、存活率和发酵性能。生理学分析发现,酸胁迫环境下,重组菌株细胞有较高的胞内NH4+、ATP含量和H+-ATPase活性,并显著提高了精氨酸脱亚胺酶(ADI)途径中的氨基酸浓度。进一步的转录分析发现,天冬氨酸合成、精氨酸代谢相关的基因转录水平上调。【结论】在L.lactis NZ9000中过量表达ASS或ASL可以引发精氨酸代谢流量的上调,进而提高了细胞的多种胁迫抗性。精氨酸合成途径广泛存在于多种微生物中,为微生物,尤其是工业微生物提高胁迫抗性提供了新思路。     

nisin Z部分操纵子基因超表达对nisin Z合成的影响

目的:构建表达载体pMG76e-nisABTCI,合成重组菌,分析nisin合成基因簇中的nisABTCI超表达对nisin生物合成的影响。方法:将nisABTCI基因克隆与表达载体pMG76e酶切后连接转化,并通过Bio-Rad Gene Pulsor电穿孔法将重组质粒载体转入Lactococcus Lactis N401中,得到重组菌株N401C。对比工程菌和原始产生菌的nisin Z产量。以16S rRNA为内参基因,通过半定量RT-PCR方法,比较分析原始菌株N401和3株重组菌株中nisin合成基因簇中的11个基因的表达情况。结果:成功构建重组菌株,重组菌株的nisin Z产量提高了70%左右。半定量RT-PCR结果表明不同菌株的nisin合成基因的表达表现出了不同的特征。与菌株N401相比,3株重组菌株的大部分基因上调了。结论:nisABTCI超表达明显地提高nisin产量约70%。上调的基因可能对nisin合成效率的提高具有关键作用。     

ptsH基因过表达对乳酸乳球菌N8自身免疫耐受性及其生理代谢的影响

目的:通过基因工程方法提高HPr蛋白编码基因ptsH在乳链菌肽(nisin)高产野生乳酸乳球菌株N8中的表达,揭示ptsH基因与乳酸乳球菌乳链菌肽耐受性等相关生物学功能的关系。方法:构建ptsH过表达质粒pLEV16-ptsH并转化至N8,使其ptsH基因过量表达,进而对比分析ptsH过表达菌株与野生菌株在生长曲线、乳链菌肽耐受性、效价、Biolog等方面的差异。结果:N8-ptsH过表达菌株与N8菌株在菌落形态、大小、表面湿滑程度及生长曲线等方面没有明显差异;ptsH基因过表达使N8菌株的乳链菌肽耐受性提高了8.3%,2个乳链菌肽耐受性相关基因nisI和nisF的表达量分别提高了15.45倍和近45倍;ptsH基因过表达略微减缓了N8菌株中乳链菌肽的产生,但乳链菌肽的最终产量略有提高;ptsH基因过表达菌株中PTS系统糖苷和磷酸化糖类的利用率比原始菌株显著提高。结论:ptsH基因主要与乳酸乳球菌的乳链菌肽耐受性有关。     

乳链菌肽产生菌的定向筛选及发酵产物的鉴定

利用乳链菌肽产生菌中nip^+nis^rsuc^+紧密连锁的原理,在添加乳链菌肽、蔗糖及溴甲酚紫的选择培养基上,从牛奶样品中定向筛选乳链菌肽产生菌。对筛选到的L. lactis1409菌株发酵产物的分析鉴定结果揭示:该产物对多种革兰氏阳性菌有强烈抑制作用,而对革兰氏阴性菌、酵母菌和霉菌无效,在pH值低的条件下对热稳定,对α—胰凝乳蛋白酶敏感,具有生物活性的蛋白质的分子量与乳链菌肽相当,而1409菌株的质粒分布与L. laclisATCC11454和L. lactis 7962不同,说明筛选到的L. laclis 1409菌株确是一株新的乳链菌肽产生菌。     

表达空肠弯曲菌CfrA蛋白重组乳酸乳球菌的构建及其免疫效果北大核心CSCD

【目的】本试验将空肠弯曲菌肠菌素受体蛋白CfrA编码基因导入食品级乳酸乳球菌表达系统,然后将重组乳酸乳球菌口服免疫鸡,降低空肠弯曲菌在鸡肠道中的定殖。【方法】利用PCR分别扩增空肠弯曲菌cfrA全基因及其N端片段,插入食品级表达载体pNZ8149多克隆位点并转化乳酸乳球菌NZ3900,通过Western blot鉴定重组菌株CfrA蛋白表达情况,同时通过筛选nisin浓度、温度、时间等诱导条件优化重组蛋白表达水平;进而将重组乳酸乳球菌经口服免疫SPF鸡,免疫后分别测定乳酸乳球菌自鸡体内的排出情况、以及诱导CfrA血清抗体和粘膜抗体水平,最后将空肠弯曲菌口服攻毒免疫后的鸡,通过测定鸡泄殖腔棉拭子中空肠弯曲菌的数目来判定口服免疫效果。【结果】Western blot检测显示CfrA全基因及其N端片段均可在重组乳酸乳球菌胞内可溶性表达,不分泌,筛选的最佳诱导表达条件为nisin浓度25 ng/mL、温度37°C、时间1 h。口服乳酸乳球菌10 d内自鸡体完全排空;鸡口服免疫后可产生CfrA蛋白特异性的血清IgG和肠粘膜sIgA抗体;重组乳酸乳球菌口服免疫后空肠弯曲菌在鸡体内的增殖速度显著低于对照组。【结论】成功构建了重组CfrA蛋白的食品级乳酸乳球菌诱导表达系统;表达CfrA蛋白的重组乳酸乳球菌口服免疫鸡对空肠弯曲菌在鸡肠道的定殖具有一定的抑制作用,为研制重组乳酸菌口服家禽免疫制剂防治空肠弯曲菌奠定了基础。     

表达猪传染性胃肠炎病毒S基因的重组乳酸乳球菌的构建及免疫原性分析

根据猪传染性胃肠炎病毒纤突(S)蛋白的全基因序列及表达载体质粒的基因融合特点,设计一对引物,进行PCR扩增,获得含有TGEVS基因4个主要抗原位点的约2000bp的目的片段,将其与分泌表达的载体质粒pNZ8112进行连接,通过电击转化进入宿主菌乳酸乳球菌NZ9000细胞内,在乳链菌肽(Nisin)的诱导下进行表达,通过SDS-PAGE和Western blot分析,表明TGEVS蛋白在乳酸乳球菌中获得表达,所表达的TGEVS蛋白具有与TGE病毒一样的抗原特异性。间接免疫荧光试验表明重组菌表达蛋白定位于菌体表面。将表达TGEVS蛋白的重组乳酸乳球菌及空质粒菌株分别口服免疫BALB/c小鼠,收集粪便样品进行抗体检测,结果表明分泌型的重组菌pNZ8112-Sa/NZ9000免疫小鼠能够产生明显的抗TGEVsIgA抗体。     

Inducible resistance against nisin in Lactobacillus casei

Most strains of Lactobacillus casei tested were found to be nisin-resistant. The addition of nisin to a growing culture of a resistant strain stopped growth for several hours; however, growth then resumed at the previous rate. Nisin induced a resistance mechanism that was lost by one passage in nisin-free medium. During induction with nisin, the cells produced an anionic, phosphate-containing polysaccharide with the subunits rhamnose and galactose. This polysaccharide protected sensitive cells of L. casei against the bactericidal action of nisin. Received: 27 July 1995 / Accepted: 30 October 1995     

Lipid-free NisI: interaction with nisin and contribution to nisin immunity via secretion

Nisin-producing Lactococcus lactis cells protect their own cytoplasmic membrane by specific immunity proteins, NisF/E/G and NisI, a transporter complex and a lipoprotein, respectively. A portion of NisI is secreted to the medium in a lipid-free form (LF-NisI). Here, kinetics of the interaction between nisin and LF-NisI was examined by surface plasmon resonance analysis. The affinity constant K_D for the interaction was calculated to be in the micromolar range. Contribution of the secreted LF-NisI to nisin immunity was studied by replacing the lipoprotein specific nisI signal sequence with a secretion signal of non-lipoprotein origin. Secretion of LF-NisI in NisF/E/G-expressing L. lactis strain NZ9840 increased significantly its nisin tolerance suggesting that the lipid-free form of NisI could have a supportive role in nisin immunity.     

Survival of nisin activity in intestinal environment

The sensitivity of nisin to proteolytical breakdown in intestinal environment was studied in an ex vivo model using jejunal chyme from fistulated dogs. Sixty six percentage of the added nisin retained induction activity after 30 min incubation in jejunal chyme, indicating that nisin has potential to be used as an inducing agent in in situ delivery systems of bioactive peptides and proteins by genetically modified bacteria in the intestine.     

Online recovery of nisin during fermentation and its effect on nisin production in biofilm reactor

An online removal of nisin by silicic acid coupled with a micro-filter module was proposed as an alternative to reduce detrimental effects caused by adsorption of nisin onto producer, enzymatic degradation by protease, and product inhibition during fermentation. In this study, silicic acid was successfully used to recover nisin from the fermentation broth of Lactococcus lactis subsp. lactis NIZO 22186. The effect of pH (at 6.8 and 3.0) during adsorption process and several eluents (deionized water, 20% ethanol, 1 M NaCl, and 1 M NaCl + 20% ethanol) for desorption were evaluated in a small batch scale. Higher nisin adsorption onto silicic acid was achieved when the adsorption was carried out at pH 6.8 (67% adsorption) than at pH 3.0 (54% adsorption). The maximum recovery was achieved (47% of nisin was harvested) when the adsorption was carried out at pH 6.8 and 1 M NaCl + 20% ethanol was used as an eluent for desorption. Most importantly, nisin production was significantly enhanced (7,445 IU/ml) when compared with the batch fermentation without the online recovery (1,897 IU/ml). This may possibly be attributed to preventing the loss of nisin due the detrimental effects and a higher biomass density achieved during online recovery process, which stimulated production of nisin during fermentation.     

The effect of nisin on murein synthesis

Nisin inhibits murein synthesis with concomitant accumulation of undecaprenyl-pyrophospho-MurNAc(pentapeptide) (lipid intermediate I). This inhibition is caused by the formation of a complex between the antibiotic and lipid intermediate I. Undecaprenyl-pyrophospho-MurNAc(pentapeptide)-GlcNAc (lipid intermediate II) also forms a complex with nisin. However, when murein synthesis is inhibited by nisin, this latter complex is not formed since lipid intermediate II is no longer synthesized.Abbreviations GlcNAc N-acetylglucosamine - MurNAc N-acetylmuramyl - Pentapeptide Ala--DGlu-Lys-DAla-DAla - C₅₅ undecaprenol Dedicated to Professor Otto Kandler on occasion of his 60th birthday     

Influence of nisin hinge-region variants on lantibiotic immunity and resistance proteins

The rising existence of antimicrobial resistance, confirms the urgent need for new antimicrobial compounds. Lantibiotics are active in a low nanomolar range and represent good compound candidates. The lantibiotic nisin is well studied, thus it is a perfect origin for exploring novel lantibiotics via mutagenesis studies. However, some human pathogens like Streptococcus agalactiae COH1 already express resistance proteins against lantibiotics like nisin.This study presents three nisin variants with mutations in the hinge-region and determine their influence on both the growth inhibition as well as the pore-forming activity. Furthermore, we analyzed the effect of these mutants on the nisin immunity proteins NisI and NisFEG from Lactococcus lactis, as well as the nisin resistance proteins SaNSR and SaNsrFP from Streptococcus agalactiae COH1.We identified the nisin variant ₂₀NMKIV₂₄ with an extended hinge-region, to be an excellent candidate for further studies to eventually overcome the lantibiotic resistance in human pathogens, since these proteins do not recognize this variant well.     

Antibacterial peptide nisin: A potential role in the inhibition of oral pathogenic bacteria

Although the antimicrobial peptide nisin has been extensively studied in the food industry for decades, its application in the oral cavity remains to develop and evaluate its feasibility in treating oral common diseases. Nisin is an odorless, colorless, tasteless substance with low toxicity and with antibacterial activities against Gram-positive bacteria. These biologic properties may establish its use in promising products for oral diseases. This article summarizes the antibacterial efficiency of nisin against pathogenic bacteria related to dental caries and root canal infection and discusses the combination of nisin and common oral drugs.     

Influence of growth conditions on the nisin production of bioengineered <Emphasis Type="Italic">Lactococcus lactis</Emphasis> strains

Nisin production of three bioengineered strains, (LAC338, LAC339 and LAC340) with immunity (nisFEG) and/or regulation (nisRK) genes of nisin biosynthesis on plasmids in the Lactococcus lactis LL27 nisin producer, was evaluated under pH-controlled and pH-uncontrolled batch fermentations. Optimization studies showed that fructose and yeast extract yielded the highest nisin activity. The strains LAC338, LAC339, and LAC340 produced 24, 45, and 44% more nisin, respectively, than wild-type L. lactis LL27 after 12-h incubation. However, sharp decreases in the yield of nisin were observed at the late phase of fermentation with LAC339 and LL27 in contrast to LAC340 and LAC338 strains for which the high level of nisin could be maintained longer. Obviously, increasing the copy number of the regulation genes together with immunity genes in the nisin producers retarded the loss of nisin in the late phase of the fermentation.